NewAmsterdam Pharma Company NV [NAMS] stock is trading at $20.02, up 2.88%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NAMS shares have gain 10.55% over the last week, with a monthly amount glided 2.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NewAmsterdam Pharma Company NV [NASDAQ: NAMS] stock has seen the most recent analyst activity on June 17, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $42. Previously, Stifel started tracking the stock with Buy rating on June 10, 2025, and set its price target to $44. On June 04, 2025, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $42 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $48 on December 30, 2024. TD Cowen initiated its recommendation with a Buy. Scotiabank started tracking with a Sector Outperform rating for this stock on March 14, 2024, and assigned it a price target of $35. In a note dated January 18, 2024, Guggenheim initiated an Buy rating and provided a target price of $30 on this stock.
NewAmsterdam Pharma Company NV [NAMS] stock has fluctuated between $14.06 and $27.29 over the past year. Currently, Wall Street analysts expect the stock to reach $41 within the next 12 months. NewAmsterdam Pharma Company NV [NASDAQ: NAMS] shares were valued at $20.02 at the most recent close of the market. An investor can expect a potential return of 104.8% based on the average NAMS price forecast.
Analyzing the NAMS fundamentals
NewAmsterdam Pharma Company NV [NASDAQ:NAMS] reported sales of 47.14M for the trailing twelve months, which represents a growth of 112.56%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -4.02%, Pretax Profit Margin comes in at -3.97%, and Net Profit Margin reading is -3.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.33 and Total Capital is -0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.44 points at the first support level, and at 18.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.43, and for the 2nd resistance point, it is at 20.85.
Ratios To Look Out For
For context, NewAmsterdam Pharma Company NV’s Current Ratio is 19.98. Also, the Quick Ratio is 19.98, while the Cash Ratio stands at 18.29. Considering the valuation of this stock, the price to sales ratio is 47.68, the price to book ratio is 2.89.
Transactions by insiders
Recent insider trading involved Topper James N, Director, that happened on Jun 24 ’25 when 2520.0 shares were purchased. Director, Topper James N completed a deal on Jun 25 ’25 to buy 1260.0 shares. Meanwhile, Chief Operating Officer Kling Douglas F sold 100000.0 shares on Jun 16 ’25.
